Rectal Cancer Clinical Trial
Official title:
Gluteal Turnover Flap for Closure of the Perineal Wound After Abdominoperineal Resection for Rectal Cancer
Background:
About 700 patients per year undergo an abdominoperineal resection (APR) for distal rectal
cancer (Dutch Colorectal Audit 2016).Neoadjuvant (chemo)radiotherapy is often used to further
improve locoregional control. Morbidity after APR is substantial and mainly consisting of
perineal wound problems in about 35% of the patients. lf primary healing of the perineal
wound after APR doesn't occur, secondary healing can take up to one year, and there is even a
small proportion of patients in whom a chronic perineal wound or fistula persists after one
year. During this long period, intensive wound care is necessary. This results in a heavy
burden on both patient and health care resources.
Objective:
The high morbidity rate of the perineal wound has resulted in a continuing discussion on how
to close the perineal defect after APR. Our research group recently published the
BIOPEX-study (NL42094.018.12), in which 104 patients were randomized between primary perinea!
wound closure and biological mesh closure of the pelvic floor after APR with preoperative
radiotherapy for rectal cancer. Similar uncomplicated perineal wound healing rate at 30 days
(Southampton wound score < 2) was found: 63% versus 66%, respectively. The hypothesis behind
this negative trial result is related to the perineal dead space between the skin and the
biological mesh. Fluid will accumulate in this dead space with the risk of secondary
contamination and abscess formation, leading to wound dehiscence and purulent discharge.
Autologous tissue flaps have been suggested to improve perineal wound healing based on
several cohort studies. At least in the Netherlands, these flaps are used only for selected
patients with the large defects and highest risk of wound problems, because of the more
extensive surgery with added surgical trauma and operative time, and associated donor site
morbidity. For these reasons, primary perineal closure (control arm of BIOPEX) is still the
standard of care in the Netherlands.
A gluteal turnover flap (GT flap) is a small transposition flap trom the unilateral adjacent
perineal skin and subcutaneous fat, which is flipped into the perineal dead space, and
stitched with the de-epithelialised dermis to the contralateral pelvic floor remnant.
Subsequently, the perineal subcutaneous fat and skin are closed over the flap in the midline,
thereby not adding a donor site scar. A small pilot study trom our group showed that this is
a promising solution for routine perineal closure after APR.
Study design:
In this multicenter single blinded study, eligible patients will be randomized between pelvic
floor reconstruction using a GT flap (intervention arm) and primary closure of the perineal
defect (standard arm). The perineal wound healing will be evaluated at 14 days and 1, 3, and
6 months post-operatively using the Southampton wound scoring system by an independent
observer.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06380101 -
Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)
|
N/A | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Recruiting |
NCT04323722 -
Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
Active, not recruiting |
NCT01347697 -
Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer
|
N/A | |
Recruiting |
NCT04495088 -
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
|
Phase 3 | |
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03520088 -
PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS
|
N/A | |
Recruiting |
NCT05556473 -
F-Tryptophan PET/CT in Human Cancers
|
Phase 1 | |
Recruiting |
NCT04749381 -
The Role of TCM on ERAS of Rectal Cancer Patients
|
Phase 2 | |
Enrolling by invitation |
NCT05028192 -
Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
|
||
Recruiting |
NCT03283540 -
Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Recruiting |
NCT05914766 -
An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
|
N/A | |
Recruiting |
NCT04852653 -
A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
|
||
Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
Terminated |
NCT02933944 -
Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
|
Phase 1 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A |